This is insane, but we suggest conducting clinical trials of aging therapies strictly on a non-commercial basis. We do not try to make money on developing a medicine for old age. Our experience and experience of Russian and foreign colleagues suggest that the attempt to earn money takes a significant part of resources and time and affects the objectivity. We will not notice how we begin to bias the results of our own research, erring in their effectiveness. With full openness, we will be able to attract expertise of any level at any stage of the study. In this case, our goal is speed and efficiency, rather than earnings.